Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Date:3/14/2012

11, decreased to $26.4 million, compared to $28.2 million in full year ended December 31, 2010. These decreases are primarily attributable to reductions in interest expense resulting from Arena's principal prepayments on its Deerfield loan of $20.0 million in January 2011 and $17.7 million in March 2011. Arena's net loss allocable to common stockholders in the fourth quarter of 2011 was $23.7 million, or $0.16 per share, compared to $28.2 million, or $0.23 per share, in the fourth quarter of 2010. Including $10.5 million of non-cash debt extinguishment charges and $3.5 million of restructuring charges, Arena's net loss allocable to common stockholders in the full year ended December 31, 2011, was $111.5 million, or $0.80 per share, compared to $124.5 million, or $1.14 per share, in the full year ended December 31, 2010, which included $12.4 million of non-cash debt extinguishment charges.

At December 31, 2011, cash and cash equivalents totaled $57.6 million and approximately 146.1 million shares of common stock were outstanding. In January 2012, Arena received net proceeds of approximately $27.9 million from its equity financing with certain Deerfield entities, after principal prepayment of $5.0 million on its Deerfield loan. In March 2012, Arena received net proceeds of approximately $24.7 million under an equity line of credit with Azimuth Opportunity, L.P. After such financings, on March 14, 2012, approximately 180.4 million shares of common stock were outstanding.

Recent Highlights

  • Filed a marketing authorization application, or MAA, for lorcaserin through the centralized procedure with the European Medicines Agency, or EMA. Arena was previously assigned the UK's Medicines and Healthcare products Regulatory Agency, or MHRA, as application Rapporteur, and Sweden's Medical Products Agency, or MPA, as Co-rapporteur. Arena expects the EMA will accept the MAA later this month and confirm the filing is sufficient to permit a substantive
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
    2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
    3. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
    4. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
    5. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    6. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
    7. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
    8. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
    9. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
    10. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
    (Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
    ... studies of its NeuroFlo(TM) ... Ischemic Stroke, MINNEAPOLIS, April 1, 2008 CoAxia(TM), ... an additional $11.5M financing,from current investors to support the ... extension of the previously announced,C Round and will allow ...
    ... 1, 2008 CV Therapeutics, Inc.,(Nasdaq: CVTX ... 57th Annual,Scientific Sessions of the American College of ... reduced the,risk of recurrent ischemia (p=0.002), worsening angina ... patients,(n=3,565) in the MERLIN- TIMI 36 study., ...
    Cached Medicine Technology:CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 3
    (Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
    (Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
    (Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
    (Date:7/9/2014)... reputation for being highly toxic, but when used in the ... to offer potential health benefits in a range of issues, ... compound (AP39), designed and made at the University of Exeter, ... of very small amounts of the substance to the right ... have already found that the compound protects mitochondria the ...
    (Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
    Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
    ... a way to predict whether women with ductal carcinoma in ... cancer are at risk of developing more invasive tumors ... women with DCIS will have the opportunity to be more ... will have much more information, so they can better know ...
    ... for Radiation Oncology (ASTRO) has released its Emerging ... body radiotherapy (SBRT) in lung cancer treatment. SBRT ... focused radiation beams to target a well-defined tumor ... planning and precise treatment setup to deliver the ...
    ... release is available in French . , Ottawa, ... ideas amongst researchers is a fundamental element in turning knowledge ... Thanks to the newly launched PubMed Central Canada (PMC Canada), ... archive of published Canadian health research. PMC Canada ...
    ... researchers find , WEDNESDAY, April 28 (HealthDay News) -- ... lung disease caused by cystic fibrosis: Which comes first, ... beginning to answer that question, and it looks like ... an assistant professor of internal medicine at the University ...
    ... ... Air” in HuffPost Living , ... (PRWEB) April 28, 2010 -- Huffington Post blogger and radio host Kathleen ... radio program, The Kathleen Show ., , ,Each week in The Huffington Post ...
    ... ... , ... 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and ... care programs in connection with its marketing and promotional practices for the blockbuster atypical ...
    Cached Medicine News:Health News:Breakthrough method predicts risk of invasive breast cancer 2Health News:Breakthrough method predicts risk of invasive breast cancer 3Health News:Canada joins international network providing free access to health research 2Health News:Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease 2Health News:The Kathleen Show Launches Weekly Audio Blog on The Huffington Post 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 3
    This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
    ... designed to enhance the chin contour, this chin ... a high-profile central chin projection. Symmetrical Chin ... this implant provides a high central projection, as ... Cleft Chin Implants - Designed with a unique ...
    The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
    ... IEC CL31 Multispeed Series offers unsurpassed ... quiet, compact, 1.2 liter benchtop centrifuge. ... and accessories and high-speed centrifugation capabilities, ... everything you need to meet a ...
    Medicine Products: